Company profile
Champions Oncology, Inc.
NASDAQ: CSBR · Healthcare · Biotechnology
#414 of 1,418 Healthcare companies by revenue59th-percentile growth
EA Score
——FH —DQ 35GM —SS 70
v0.1 · 25/100 weight · pillars only
↑ return on equity, return on assets · ↓ Piotroski F, filing timeliness
Methodology →Revenue TTM
$57.9M
Rev growth YoY (TTM)
-1.1%
Net income (FY)
$4.7M
Employees
214
as of 2026-08-18
Market cap
$72.4M
as of 2026-08-18
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$56.9M$56.9M2025
Net income$4.7M$4.7M2025
Operating income$4.6M$4.6M2025
Total assets$32.3M$32.3M2025
Liabilities$28.6M$28.6M2025
Equity$3.8M$3.8M2025
Revenue trend
FY2019 – FY2025 · USD
FY19
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Pharmacology Services85%
License and Maintenance8%
Product and Service, Other6%
By geography
Not disclosed.
The read
What is Champions Oncology, Inc.’s revenue?
Champions Oncology, Inc. booked $56.9M in FY2025 revenue, growing 14% year over year — about the middle of the pack among Healthcare companies we track, at a 8.3% net margin.
Peers · Healthcare
Kestra Medical Technologies, Ltd.——Etao International Co., Ltd.——Flower One Holdings Inc.——CVRx, Inc.50DHLS Therapeutics Inc.64C908 Devices Inc.60CNeighbors
Bergen →Key facts
CEORobert Brainin
SectorHealthcare
IndustryBiotechnology
HeadquartersHackensack, NJ
ExchangeNASDAQ: CSBR
Employees214
IPO date2007-02-02
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.